Your browser doesn't support javascript.
loading
In vitro and in vivo characterization of a novel naphthylamide ATP-sensitive K+ channel opener, A-151892.
Gopalakrishnan, Murali; Buckner, Steven A; Shieh, Char-Chang; Fey, Thomas; Fabiyi, Adebola; Whiteaker, Kristi L; Davis-Taber, Rachel; Milicic, Ivan; Daza, Anthony V; Scott, Victoria E S; Castle, Neil A; Printzenhoff, David; London, Brecht; Turner, Sean C; Carroll, William A; Sullivan, James P; Coghlan, Michael J; Brune, Michael E.
Afiliación
  • Gopalakrishnan M; Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA. mural.gopalakrishnan@abbott.com
Br J Pharmacol ; 143(1): 81-90, 2004 Sep.
Article en En | MEDLINE | ID: mdl-15302680
ABSTRACT
1. Openers of ATP-sensitive K(+) channels are of interest in several therapeutic indications including overactive bladder and other lower urinary tract disorders. This study reports on the in vitro and in vivo characterization of a structurally novel naphthylamide N-[2-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-naphthalen-1-yl]-acetamide (A-151892), as an opener of the ATP-sensitive potassium channels. 2. A-151892 was found to be a potent and efficacious potassium channel opener (KCO) as assessed by glibenclamide-sensitive whole-cell current and fluorescence-based membrane potential responses (-log EC(50)=7.63) in guinea-pig bladder smooth muscle cells. 3. Evidence for direct interaction with KCO binding sites was derived from displacement of binding of the 1,4-dihydropyridine opener [(125)I]A-312110. A-151892 displaced [(125)I]A-312110 binding to bladder membranes with a -log Ki value of 7.45, but lacked affinity against over 70 neurotransmitter receptor and ion channel binding sites. 4. In pig bladder strips, A-151892 suppressed phasic, carbachol-evoked and electrical field stimulus-evoked contractility in a glibenclamide-reversible manner with -log IC(50) values of 8.07, 7.33 and 7.02 respectively, comparable to that of the potencies of the prototypical cyanoguanidine KCO, P1075. The potencies to suppress contractions in thoracic aorta (-log IC(50)=7.81) and portal vein (-log IC(50)=7.98) were not substantially different from those observed for suppression of phasic contractility of the bladder smooth muscle. 5. In vivo, A-151892 was found to potently suppress unstable bladder contractions in obstructed models of unstable contractions in both pigs and rats with pED(35%) values of 8.05 and 7.43, respectively. 6. These results demonstrate that naphthylamide analogs exemplified by A-151892 are novel K(ATP) channel openers and may serve as chemotypes to exploit additional analogs with potential for the treatment of overactive bladder and lower urinary tract symptoms.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Canales de Potasio / Adenosina Trifosfato / Acetamidas / Naftalenos Tipo de estudio: Diagnostic_studies Límite: Animals Idioma: En Revista: Br J Pharmacol Año: 2004 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Canales de Potasio / Adenosina Trifosfato / Acetamidas / Naftalenos Tipo de estudio: Diagnostic_studies Límite: Animals Idioma: En Revista: Br J Pharmacol Año: 2004 Tipo del documento: Article País de afiliación: Estados Unidos